Trial Profile
Phase II Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Urothelial Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2018
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 26 Oct 2017 Status changed from recruiting to discontinued.
- 19 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 01 Oct 2015 New trial record